John Schaeffer, DO
Neurology · Missoula, MTNPI 1770536872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 79.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $391 and has fallen 64.9% since, to $137 in 2025.
Across 79 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$175
- UCB, Inc.$56
- Biogen$32
- Lilly USA, LLC$13
- Acorda Therapeutics, Inc$11
What the payments were for
- Speaking & faculty fees$111%
- Food & beverage$1,38499%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $1,107 |
| Novartis | 20 | $175 |
| UCB, Inc. | 4 | $56 |
| Biogen | 2 | $32 |
| Lilly USA, LLC | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $11 |
How this compares
$1,395 in reported general payments places this provider in the 55th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zonisamide | 12 | $243 |
Paid to pharmacies, not to this prescriber.
Other neurology in Missoula
- Thomas SwansonMissoula$11K
- Sarah KochMissoula$2K
- Kyle SmithMissoula$1K
- Aakriti BertscheMissoula$421
- Michael YoungMissoula$44
- Lennard WilsonMissoula$0
- Ann CollierBillings$164K
- Dennis DietrichGreat Falls$140K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.